Loading...

APC anti-mouse Ly-6C Antibody

Pricing & Availability
Clone
HK1.4 (See other available formats)
Regulatory Status
RUO
Other Names
Lymphocyte antigen 6 complex, locus C
Isotype
Rat IgG2c, κ
Ave. Rating
Submit a Review
Product Citations
publications
HK1dot4_APC_082509
C57BL/6 bone marrow cells stained with HK1.4 APC
  • HK1dot4_APC_082509
    C57BL/6 bone marrow cells stained with HK1.4 APC
Compare all formats See APC spectral data
Cat # Size Price Save
128015 25 µg ¥25,520
128016 100 µg ¥62,920
Description

Most hematopoietic cells express one or more members of Ly-6 family. The expression of Ly-6 varies with development stage and activation. Ly-6C is a 14-17 kD GPI-linked surface protein expressed on mouse monocyte/macrophage cells, endothelial cells, neutrophils, and some T cell subsets. Ly-6C is reported to be an indicator of memory CD8+ T cells.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
L3 cloned CTL cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone HK1.4 does not block the binding of clone RB6-8C58.

Additional reported applications (for relevant formats of this clone) include: in vitro activation of T cells1-3 and immunohistochemistry of frozen sections4.

Application References

(PubMed link indicates BioLegend citation)
  1. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819. (Activ)
  2. Herold KC, et al. 1990. Diabetes 39:815. (Activ)
  3. Havran WL, et al. 1988. J. Immunol. 140:1034 (Activ)
  4. Flanagan K, et al. 2008. J. Immunol. 180:3874. (IHC)
  5. Makaroff LE, et al. 2009. P. Natl. Acad. Sci. USA 106:4799. (FC)
  6. Zuber J, et al. 2009. Genes Dev. 23:877. (FC) PubMed
  7. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
  8. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
  9. Watson NB, et al. 2015. J Immunol. 194:2796. PubMed
Product Citations
  1. Guo H, et al. 2020. Curr Protoc Immunol. 131:e107. PubMed
  2. Pierson M, et al. 2021. Curr Protoc. 1:e53. PubMed
  3. Alam A, et al. 2022. Cancer Cell. 40:153. PubMed
  4. Bettke JA, et al. 2022. Infect Immun. 90:e0007022. PubMed
  5. Dolfi B, et al. 2022. Cell Rep. 39:110949. PubMed
  6. Blanco LP, et al. 2022. Arthritis Rheumatol. 74:1971. PubMed
  7. Poh AR, et al. 2022. Cell Rep. 41:111479. PubMed
  8. Gong F, et al. 2023. Adv Healthc Mater. 12:e2201771. PubMed
  9. Papaxenopoulou LA, et al. 2022. iScience. 25:105522. PubMed
  10. Urata S, et al. 2023. Microbiol Immunol. 67:105. PubMed
  11. He Y, et al. 2023. Nat Commun. 14:691. PubMed
  12. Drummer C, et al. 2023. Front Immunol. 14:1113883. PubMed
  13. MohanKumar K, et al. 2019. Nat Commun. 10:3494. PubMed
  14. Hamdan F, et al. 2023. Mol Ther Oncolytics. 28:264. PubMed
  15. Saha S, et al. 2023. Sci Rep. 13:4609. PubMed
  16. Fukuzaki Y, et al. 2023. iScience. 26:106340. PubMed
  17. Cozzolino M, et al. 2023. Int J Mol Sci. 24:. PubMed
  18. Yang QC, et al. 2023. iScience. 26:106916. PubMed
  19. Tebartz C, et al. 2015. J Immunol. 194:1100. PubMed
  20. D'Alessandro G, et al. 2020. Eur J Immunol. 50:705. PubMed
  21. Tan L, et al. 2022. Biochem Biophys Rep. 32:101351. PubMed
  22. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  23. Borggrewe M, et al. 2018. Glia. 66:2645. PubMed
  24. Iwamoto H et al. 2018. Cell metabolism. 28(1):104-117 . PubMed
  25. Aggen DH, et al. 2020. Clin Cancer Res. . PubMed
  26. Kim JS, et al. 2020. Immunity. 54(1):176-190.e7. PubMed
  27. Nocera D, et al. 2016. J Immunol. 196: 2860 - 2869. PubMed
  28. Rosenheinrich M, et al. 2015. PLoS One. 10: 0136290. PubMed
  29. Jahan S, et al. 2022. J Biol Chem. :102386. PubMed
  30. Kurelac I, et al. 2019. Nat Commun. 10:903. PubMed
  31. Price P, et al. 2014. J Virol. 88:10840. PubMed
  32. Zasłona Z, et al. 2014. J Immunol. 193:4245. PubMed
  33. Su N, Xiong Y 2016. Sci Rep. 6:22658. PubMed
  34. Shu T, et al. 2022. Eur Respir J. Online ahead of print. PubMed
  35. Cheng G, et al. 2021. iScience. 24:102673. PubMed
  36. Biffi G, et al. 2018. Cancer Discov. 2:282. PubMed
  37. Pingili AK, et al. 2021. Cell Reports. 35(12):109285. PubMed
  38. Earnest JT, et al. 2021. Cell Reports. 35(1):108962. PubMed
  39. Liang W, et al. 2020. Nat Commun. 4.563888889. PubMed
  40. Zhang X, et al. 2022. J Neuroinflammation. 19:111. PubMed
  41. Ye M, et al. 2022. Nat Nanotechnol. 17:880. PubMed
  42. Lubkin A et al. 2019. Cell host & microbe. 25(3):463-470 . PubMed
  43. Dave K et al. 2017. eLife. 6 pii: e23382. PubMed
  44. Murphy M, et al. 2017. Eur J Immunol. 47:880. PubMed
  45. Getts D, et al. 2014. Sci Transl Med. 15:219. PubMed
  46. Martin R, et al. 2014. J Leukoc Biol. 96:151. PubMed
  47. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  48. Godbersen-Palmer C, et al. 2020. J Immunol. 204:2973. PubMed
  49. Mastandrea I, et al. 2022. STAR Protoc. 3:101106. PubMed
  50. Kienzl M, et al. 2020. Oncoimmunology. 9:1776059. PubMed
  51. Werneburg S, et al. 2020. Immunity. 52(1):167-182.e7.. PubMed
  52. Anderson MC, et al. 2018. Cell Chem Biol. 25:483. PubMed
  53. Pan W et al. 2017. Immunity. 47(2):284-297 . PubMed
  54. Magod P, et al. 2021. Cell Reports. 36(5):109480. PubMed
  55. Ray A, et al. 2014. J Immunol. 192:5109. PubMed
  56. Zhang J, et al. 2022. iScience. 25:104963. PubMed
  57. Parlet CP, et al. 2019. Cell Rep. 27:187. PubMed
  58. Green DP, et al. 2019. Neuron. 101:412. PubMed
  59. Zhang S, et al. 2019. Cell Metab. 29:443. PubMed
  60. Chakraborty S, et al. 2022. Sci Transl Med. . PubMed
  61. Li Y, et al. 2021. Brain Behav Immun. 91:267. PubMed
  62. Korangath P, et al. 2020. Bio Protoc. 10:e3822. PubMed
  63. Ajina R, et al. 2021. Cancer Immunol Res. 9:386. PubMed
  64. McLaughlin PA et al. 2019. PLoS Pathog. 15(7):e1007847 . PubMed
  65. Ye Z, et al. 2019. Mediators Inflamm. 2019:8709583. PubMed
  66. Ohgomori T, et al. 2020. Neuropharmacology. 176:108227. PubMed
  67. Tanaka T, et al. 2015. J Immunol. 194:2004. PubMed
  68. Mao FY, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:395. PubMed
  69. Morales-Mantilla DE, et al. 2022. Elife. 11:. PubMed
  70. Codina A, et al. 2019. Cell Syst. 8:136. PubMed
  71. Derecka M, et al. 2020. Nat Immunol. 261:21. PubMed
  72. Heng Y, et al. 2021. J Neuroinflammation. 18:57. PubMed
  73. Christ A, et al. 2018. Cell. 172:162. PubMed
  74. Hepler C et al. 2018. eLife. 7 pii: e39636. PubMed
  75. Radjabova V, et al. 2015. J Immunol. 195: 3149 - 3159. PubMed
  76. Kuhn JA, et al. 2021. Elife. 10:. PubMed
  77. Liu H, et al. 2022. Front Pharmacol. 13:949316. PubMed
  78. Deczkowska A, et al. 2017. Nat Commun. 8:717. PubMed
  79. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  80. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  81. Guldner IH, et al. 2020. Cell. 183(5):1234-1248.e25. PubMed
  82. Shao M, et al. 2021. Cell Stem Cell. 28(4):685-701.e7. PubMed
  83. Liu X, et al. 2021. Int J Nanomedicine. 16:5675. PubMed
  84. Kolodziejczyk AA, et al. 2020. Nat Med. 26:1899. PubMed
  85. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  86. Pundir P, et al. 2020. Cell Host & Microbe. 26(1):114-122. PubMed
  87. Joffin N, et al. 2021. Cell Stem Cell. 28(4):702-717.e8. PubMed
  88. Ritzel RM, et al. 2021. Glia. 69:746. PubMed
  89. Sauter K, et al. 2014. J Leukoc Biol. 96:265. PubMed
  90. Yu W, et al. 2022. Nat Commun. 13:3544. PubMed
  91. Ryan NM, et al. 2022. Front Immunol. 13:932742. PubMed
  92. Lingegowda H, et al. 2022. Front Reprod Health. 3:726936. PubMed
  93. Melo-Silva CR, et al. 2021. PLOS Pathogens. 17(5):e1009593. PubMed
  94. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  95. Zhou J, et al. 2022. Int J Oncol. 61: . PubMed
  96. Shan B, et al. 2020. Nat Metab. 1332:2. PubMed
  97. Wong NR, et al. 2021. Immunity. 54:2072. PubMed
  98. Clemente C, et al. 2018. Nat Commun. 9:910. PubMed
  99. Wang T et al. 2018. Immunity. 49(3):504-514 . PubMed
  100. Ohgomori T et al. 2019. J Comp Neurol. 528(1):14-31 . PubMed
  101. Alexander Mildner et al. 2017. Immunity. 46(5):849-862 . PubMed
  102. Bordas M, et al. 2020. Int J Mol Sci. 21:00. PubMed
  103. Varikuti S, et al. 2020. Br J Cancer. 122:1005. PubMed
  104. Karki R, et al. 2020. bioRxiv. . PubMed
  105. Li N, et al. 2022. Nat Commun. 13:7281. PubMed
  106. Liu R, et al. 2020. Eur J Vasc Endovasc Surg. 60:254. PubMed
  107. Steele NG, et al. 2021. Clin Cancer Res. 27:2023. PubMed
  108. Karki R, et al. 2021. Cell. 184:149. PubMed
  109. Huo M, et al. 2017. FASEB J. 10.1096/fj.201601030R. PubMed
  110. Mukovozov I, et al. 2015. J Immunol. 195: 3334 - 3344. PubMed
  111. Chen L, et al. 2021. Theranostics. 11:6668. PubMed
  112. Li Y, et al. 2022. Theranostics. 12:5364. PubMed
  113. Ding L et al. 2018. Cell reports. 25(11):2972-2980 . PubMed
  114. Schaftenaar FH, et al. 2019. Sci Rep. 9:17391. PubMed
  115. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
  116. Molgora M, et al. 2020. Cell. 182:886. PubMed
  117. Li Y, et al. 2020. Theranostics. 10:11376. PubMed
  118. Hsia HC, et al. 2017. J Leukoc Biol. 101:1053. PubMed
  119. Kitamoto S, et al. 2020. Cell. 182(2):447-462.e14. PubMed
  120. Kratochvill F, et al. 2015. Cancer Res. 75: 3054-3064. PubMed
  121. Pisano F, et al. 2014. PLoS One. 9:103541. PubMed
  122. Shin SH, et al. 2022. Clin Exp Otorhinolaryngol. . PubMed
  123. Rivera CA, et al. 2022. Immunity. 55:129. PubMed
  124. Ghosh S, et al. 2019. Commun Biol. 0.325. PubMed
  125. Collins C, et al. 2014. Proc Natl Acad Sci U S A. 111:9899. PubMed
  126. Tran S, et al. 2020. Immunity. 53(3):627-640.e5. PubMed
  127. Hamdan F, et al. 2021. Journal for ImmunoTherapy of Cancer. 9(8):. PubMed
  128. Tian T, et al. 2020. Cancer Immunol Res. 660:8. PubMed
  129. Qu J, et al. 2021. Int J Biol Sci. 17:2756. PubMed
  130. Kim I et al. 2015. Brain and behavior. 5(12):e00403 . PubMed
  131. Zhang X, et al. 2020. Glia. . PubMed
RRID
AB_1732087 (BioLegend Cat. No. 128015)
AB_1732076 (BioLegend Cat. No. 128016)

Antigen Details

Structure
14-17 kD protein (134 amino acids), member of the Ly-6 family of GPI linked protein. Ly6 family members share structure homology throughout a distinctive cystein rich protein domain that incorporates O-linked carbohydrates.
Distribution

Ly-6C is expressed primarily on bone marrow myeloid populations, monocytes/macrophages, neutrophils, endothelial cells, and some T cell subsets. Ly-6C is also a marker of memory CD8+ T cells.

Cell Type
Endothelial cells, Macrophages, Monocytes, Neutrophils, T cells
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819.
2. Cerwenka A, et al. 1998. J. Immunol. 161:97.

Gene ID
17067 View all products for this Gene ID
UniProt
View information about Ly-6C on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 2    Revision Date: 12/09/2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account